Title

Correlates of Intersectional HIV and Substance Use Stigma Affecting People with HIV and Substance Use in St. Petersburg, Russia.

Permalink

https://escholarship.org/uc/item/30h9004g

Journal

AIDS and Behavior, 27(2)

Authors

Lodi, Sara
Rossi, Sarah
Bendiks, Sally
et al.

Publication Date

2023-02-01

DOI

10.1007/s10461-022-03781-8

Peer reviewed

Correlates of intersectional HIV and substance use stigma affecting people with HIV and substance use in St. Petersburg, Russia

Sara Lodi[1], **Sarah L Rossi**[2], **Sally Bendiks**[2], **Natalia Gnatienko**[2], **Christine Lloyd-Travaglini**[1], **Marina Vetrova**[3], **Olga Toussova**[3], **Natalia Bushara**[3], **Elena Blokhina**[3], **Evgeny Krupitsky**[3,4], **Maria L Ekstrand**[5,6], **Dmitry Lioznov**[3], **Jeffrey H. Samet**[1,2,7], **Karsten Lunze**[2,7]

[1] Boston University School of Public Health, Boston, MA, USA

[2] Department of Medicine, Boston Medical Center, Boston, MA, USA

[3] Laboratory of Clinical Psychopharmacology of Addictions, First Pavlov State Medical University of Saint Petersburg, St. Petersburg, Russia

[4] Department of Addiction, Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russia

[5] Center for AIDS Prevention Studies, School of Medicine, University of California San Francisco, San Francisco, CA, USA

[6] St. John's Research Institute, St. John's National Academy of Health Sciences, Bangalore, India

[7] School of Medicine, Boston University, Boston, MA, USA

Abstract

People with HIV (PWH) who inject drugs often experience coexisting HIV- and substance use-related stigma manifestations. We assessed correlates of HIV stigma (Berger HIV stigma scale), substance use stigma (Substance Abuse Self-Stigma scale) and intersectional HIV and substance use stigma in a cohort of PWH with a lifetime history of drug use in St. Petersburg, Russia. Intersectional stigma was defined as having a score greater than the median for both forms of

stigma. Of the 208 participants, 56 (27%) had intersectional stigma. Depressive symptoms and alcohol dependence were significantly associated with a higher HIV and substance stigma score, but not with intersectional stigma. Individual and community interventions to reduce the impact of HIV stigma and substance use stigma affecting PWH who inject drugs should consider assessing and addressing mental health and unhealthy substance use. Further work with longitudinal data is needed to understand mechanisms leading to intersectional stigma.

Resumen

Las personas infectadas por el VIH que se inyectan drogas a menudo experimentan manifestaciones de estigma relacionadas con el uso de sustancias y el propio VIH. En este estudio evaluamos los correlatos de estigma asociado al VIH (escala de estigma asociado al VIH de Berger), el estigma asociado al uso de sustancias ("Substance Abuse Self-Stigma Scale") y el estigma interseccional del VIH y el uso de sustancias en una cohorte de personas infectadas por el VIH con antecedente de uso de drogas en San Petersburgo, Rusia. El estigma interseccional se definió como una puntuación superior a la mediana para ambas formas de estigma. De los 208 participantes, 56 (27%) tenían estigma interseccional. Los síntomas depresivos y la dependencia del alcohol se asociaron significativamente con una puntuación más alta de estigma relacionado con el VIH y las sustancias, pero no con el estigma interseccional. Las intervenciones individuales y comunitarias para reducir el impacto del estigma asociado al VIH y al uso de sustancias que afectan a las personas con VIH que se inyectan drogas deben tener en cuenta la salud mental y el uso nocivo de sustancias. Se necesitan estudios con datos longitudinales para comprender mejor los mecanismos que conducen al estigma interseccional.

Keywords

HIV; substance use; stigma; intersectional stigma

Introduction

Stigma is defined as the social exclusion and dehumanization of individuals assigned to an undesirable social category (1). When people with HIV (PWH) perceive negative attitudes and experience or expect stigma and discrimination, they might endorse the negative feelings and beliefs held by others about their HIV status and apply these feelings to themselves (2). In the presence of a power imbalance, enacted, anticipated, and internalized stigma may make PWH feel inferior to others and lower their social status (3). Several studies have shown that such HIV stigma manifestations adversely impact the initiation and adherence to antiretroviral treatment (ART), HIV status disclosure, and physical and mental health among PWH (4–11).

PWH with ongoing or past substance use might also internalize societal stigma because of their substance use, leading to lower self-respect and decreased self-esteem. Analogous to HIV stigma, substance use stigma adversely affects an individual's chance to engage in substance use treatment (12–14). When individuals experience both forms of stigma, the resulting intersectional stigma might adversely impact their health care and health in a way that is not merely additive (15–17). For example, previous studies have shown that among

PWH who use substances, high levels of both internalized HIV and substance use stigma were negatively associated with health status and health service utilization compared to those with low levels of at least one type of stigma (15, 18, 19).

Ending the HIV epidemic globally requires reducing and eliminating stigma as a health care barrier for the key HIV population of PWH who inject drugs. Therefore, interventions addressing intersectional substance use and HIV stigma are needed to improve care for this key population by helping them cope with stigma. This is particularly relevant in settings where HIV incidence and prevalence continue to rise due to injection drug use. In the Russian Federation (Russia) where more than one million people are registered with HIV (20, 21) 47% of incident HIV cases with a known mode of transmission are among people who inject drugs (22).

In order to develop interventions targeting stigma that affects PWH who inject drugs, we need to understand what individual characteristics correlate with intersectional HIV and substance use stigma. For instance, women seem to be more affected than men by various forms of stigma, particularly women who use substances (23–27). Other factors amenable to targeted interventions like depressive symptoms, social support, and substance use are commonly associated with various forms of health-related stigma (28). However, to our knowledge, the association between these predictors and intersectional HIV and substance use stigma have not been investigated quantitatively in the key population of PWH who inject drugs (29).

In a cohort of PWH in St. Petersburg, Russia, who had a lifetime history of drug use and were ART-naïve at enrollment, we examined whether gender, social support, alcohol dependence, depressive symptoms, recent injection drug use, history of transactional sex, and time since HIV diagnosis were associated with intersectional stigma.

Methods

Study design and population

We performed a secondary analysis of the Russia Alcohol Research Collaboration on HIV/AIDS (ARCH) cohort, a prospective observational study conducted in St. Petersburg, Russia (30). The ZINC trial was a nested double-blinded randomized controlled trial of zinc supplementation within the Russia ARCH cohort (31).

Participants in the Russia ARCH cohort (n=351, nested ZINC trial n=254) were recruited between November 2012 and June 2015 in St. Petersburg from clinical HIV and addiction care sites, among participants who had previously completed clinical studies at Pavlov State Medical University (e.g., through NGOs), and through snowball recruitment. Eligibility criteria were the following: 18–70 years old, documented HIV infection, documented ART-naïve status at enrollment, the ability to provide contact information for two contacts to assist with follow-up, stable address within 100 kilometers of St. Petersburg, possession of home or mobile phone, past month risky drinking as defined by NIAAA criteria (ZINC participants only) (32). Participants were excluded if they were not fluent in Russian or had a cognitive impairment as assessed by the research assessor resulting in the inability

to provide informed consent. The baseline assessment included the following sections: demographics (33), sex partners and behaviors (34), screening for harmful drinking and alcohol dependence per AUDIT, drug use (modified Risk Behavior Survey) (35, 36), and the VR-12 Health Survey (37). Demographic characteristics included gender, age, education (up to nine grades vs. ten grades or more of education), and employment status (working full or part time vs. not employed). Laboratory values such as CD4 count levels and HIV-1 viral loads were collected at baseline and 3 months unless clinically indicated for more. CD4 count was measured by flow cytometry. All assessments were conducted by trained research assessors and administered in Russian. Particularly sensitive sections of the assessment, including sex behaviors, were self-administered by the participant.

For the present study, we restricted inclusion to individuals who reported a lifetime history of drug use at baseline, and who completed an HIV stigma and a substance use stigma questionnaire during a study visit. The lifetime history of drug use was defined as reporting a past or recent use of drugs including heroin, opioid, cocaine, amphetamine, marijuana, or a sedative. We used baseline data for all variables except for the substance use stigma that was measured once at either baseline or a follow-up visit. In all patients who participated in the nested ZINC trial, the baseline data were collected before receiving the trial intervention.

All participants provided written informed consent, and interviews were conducted in a private space at the research center located at the Pavlov State Medical University. All participants received 600 – 1,500 Russian rubles in cash at each visit (depending on the procedures at the respective visit, the equivalent of about US $14–35 at the time of study) as compensation for their time and transportation costs. The Institutional Review Boards of Boston University Medical Campus and the First St. Petersburg Pavlov State Medical University approved this study.

Outcomes/dependent variables

We analyzed the following outcomes separately: intersectional HIV and substance use stigma (primary outcome), HIV stigma and substance use stigma (separately, secondary outcomes).

HIV stigma was quantified using the abbreviated "Berger HIV Stigma Scale," (38) a previously validated tool that includes 10 items with subscales for personalized stigma, disclosure concerns, negative self-image, and concerns with public attitudes toward HIV-positive people (i.e., "I have stopped socializing with some people because of their reaction to my having HIV"). The response options ranged from 1 "strongly disagree" to 4 "strongly agree." The HIV stigma score was calculated as the sum of each participant's response to all questions and could range from 10 to 40 points.

Substance use stigma manifestations were quantified using an abbreviated Substance Abuse Self-Stigma Scale (SASSS) (39), a previously validated tool to measure stigma among individuals with a history of substance use, as well as the Stigma-related rejection scale (SRS) (19, 40). The abbreviated SASSS consisted of 12 items with four questions in each of the three following subscales: (1) internalized/stigma, self-devaluation (4 items; e.g., "I have the thought that a major reason for my problems with substances is my own poor

character", 1=never or almost never to 5=very often), (2) fear of enacted stigma (4 items; e.g., "People think I'm worthless if they know about my substance use history", 1=few people to 5=almost everyone), (3) anticipated stigma and related avoidance (4 items; e.g., "I would choose to avoid someone who seemed interested in my friendship if I knew they had never used substances", 1=never or almost never true to 5=always or almost always true which was scored from). The substance use stigma score was calculated as the sum of each participant's response to all questions and could range from 12 to 60 points. Internal consistency of the HIV stigma and of the substance use stigma scores was assessed using a Cronbach alpha, in which a score equal or higher than 0.7 is acceptable (41).

Intersectional HIV and substance use stigma was quantified as an ordinal variable with 3 mutually exclusive categories: i) intersectional stigma defined as a high score (above the median) for both HIV *and* substance use stigma; ii) single stigma defined as either a high HIV stigma *or* a high substance use stigma score (defined as > median), with the other form of stigma low; iii) low stigma defined as lower stigma scores (median) for both HIV and substance use stigma. As a sensitivity analysis we used the 75th percentile instead of the median as cut off for high versus low stigma score.

Independent variables

Potential correlates of intersectional stigma were chosen a priori, and included social support, injection drug use in the past 30 days, depressive symptoms, gender, alcohol dependence, transactional sex, and time since HIV diagnosis (<1 year versus 1 year) measured at baseline. Social support was defined as a binary variable using the Social Support Scale (42), which is a 5-item questionnaire. Social support was defined as having a score above or equal to the 75th percentile. Depressive symptoms were defined as a score 16 on CES-D (43, 44).

Alcohol dependence in the past 12 months was defined as screening positive for probable alcohol dependence with an AUDIT score 13 in women and 15 in men (45). Transactional sex was defined as reported lifetime history of *selling* sex for money, drugs, or alcohol.

Statistical analyses

Frequencies, medians, and interquartile range [IQR] were calculated to describe the study population. We computed Spearman correlation coefficients to detect potential pairs of highly correlated independent variables, defined as a correlation > 0.4.

To accommodate the ordinal nature of the primary outcome, intersectional stigma (a 3-category variable: intersectional stigma, single stigma, low stigma), we used multinomial logistic regression models to examine its association between the independent variables. With this approach two logistic regression models are estimated simultaneously: one for the logit of intersectional stigma versus single stigma and one for the logit of single stigma versus low stigma.

We also used linear regression models to identify dependent variables associated with the continuous HIV stigma score and substance use stigma scores (secondary outcomes).

For all outcomes, we first estimated a series of unadjusted models, one for each independent variable in turn. Then, we estimated one overall model adjusting for all these variables without any further selection.

Two individuals with missing values on the transactional sex variable were excluded from the adjusted analyses.

Statistical significance for all models was set at 0.05 and all tests were two-sided. Analyses were conducted using the statistical package SAS 9.4 (SAS Institute, Inc. NC, USA).

Results

Of 351 individuals enrolled in the Russia ARCH study, 318 reported lifetime history of drug use. The present study included 208 out of 318 individuals who completed the HIV stigma and the substance use stigma questionnaire. Individuals who were excluded were more likely to be males, to have had recent drug use, to have social support, and to have higher CD4 cell count (Appendix Table I). Baseline characteristics for the 208 study participants are shown in Table I. The median [IQR] age of participants was 33 years [31,37], and 141 (68%) were male. Among 160 individuals with an available CD4 cell count, the median [IQR] was 470 cells/ml^3 [305,710]. Depressive symptoms were common (46%), as was alcohol dependence (56%). Eighty-one participants (39%) reported injection drug use in the past 30 days and 17 (8%) reported a history of transactional sex.

The median [IQR] HIV stigma score, with a possible range of 10 to 40, was 21 [17,25]. The median [IQR] substance use stigma score, with a possible range of 12 to 60, was 29 [23,37]. Cronbach alpha values for HIV stigma score and for substance use stigma score were 0.90 and 0.91, respectively, indicating internal consistency.

A total of 57 participants (27%) were classified as having higher intersectional stigma (both HIV and substance use stigma score above the median), 74 (36%) reported single stigma (a score above the median in only one of the two stigma forms), and 77 (37%) reported low stigma (both stigma scores equal to or below the median). Spearman correlation coefficients were estimated between pairs of independent variables and there was no pair with correlations greater than 0.4.

Table II shows the results of linear regression models for continuous HIV stigma scores and for continuous substance use stigma scores. In the fully adjusted models, depressive symptoms and alcohol dependence were significantly associated with a higher HIV stigma score with β parameters of 4.01 (95% confidence intervals (CI) 2.55,5.47, t=5.42, p<0.0001) and 1.68 (95% CI 0.22,3.15, t=2.27, p=0.0245), respectively. While a history of transactional sex correlated with increased HIV stigma, this variable was not significant in the adjusted model (t=1.70, p=0.0912). Depressive symptoms, recent injection drug use, and alcohol dependence were significantly associated with higher substance use stigma scores with adjusted β parameters of 6.99 (95% CI 4.54,9.43, t=5.63, p<0.0001), 4.71 (95% CI 2.22,7.21, t=3.73, p=0.0003), and 3.31 (95% CI 0.85,5.76, t=2.66, p=0.0085), respectively.

Table III shows the results of the multinomial logistic regression models. The last two columns on the right report the unadjusted and adjusted estimated odds ratios (OR) between the independent variables and the logit of single stigma versus low stigma. An OR greater than 1 indicates that increases in the independent variable lead to a higher likelihood of experiencing single stigma versus no stigma. The odds of single stigma versus low stigma in individuals with depressive symptoms were 8.06 (95% CI 3.52,18.52, Chi-square=24.23, p<0.0001) times the odds of individuals without depressive symptoms. Individuals with alcohol dependence had 2.54 (95% CI 1.18,5.49, Chi-square=5.67, p=0.0172) times the odds of a single form of stigma versus low stigma of individuals with no alcohol dependence. The adjusted model indicated that individuals who had been diagnosed with HIV for more than 1 year had 0.10 (95% CI 0.02,0.57, Chi-square=6.80, p=0.0091) the odds of a single form of stigma versus low stigma than individuals with a more recent diagnosis.

The second and third columns of Table III report the unadjusted and adjusted estimated OR between the independent variables and the logit of intersectional stigma versus a single form of stigma. An OR greater than 1 indicates that increases in the independent variable lead to a higher likelihood of experiencing intersectional stigma versus a single form of stigma. In the unadjusted model, individuals with depressive symptoms had 2.25 (95% CI 1.07,4.76, Chi-square=4.55, p=0.0330) times the odds of experiencing intersectional stigma versus single stigma than individuals without depressive symptoms. No other independent variable was significantly associated with intersectional stigma in the unadjusted and adjusted models. These results did not materially change in the sensitivity analysis using the 75th percentile as a cut-off to define high versus low stigma (Appendix Table II).

Discussion

Stigma related to HIV and substance use is considered to be widespread among PWH who use drugs in Russia and elsewhere. We examined individual and contextual correlates of stigma manifestations in the key population of PWH who use drugs. We found that depressive symptoms and alcohol dependence - but not social support, gender, history of transaction sex and time since HIV diagnosis - were independently associated with both increased HIV and substance use stigma scores. Recent injection drug use was a significant predictor of an increased substance use stigma score, but not of HIV stigma score. We did not find any significant association between any of the examined factors and intersectional HIV and substance use stigma.

The lack of association between the examined factors and intersectional stigma can be due to the overall small sample size of the study and the relatively small number and proportion of individuals classified as having intersectional stigma (i.e., 57 [27%] in the main analysis when we used the median as cut-off and 16 [8%] when we used the 75th percentile as cut-off). This suggests that individuals in which the two forms of stigma intersected according to our operationalization (i.e., manifested in high stigma scores for both scales) were not common in our sample.

Alternatively, the instruments we used might not have been adequate to quantify how HIV and substance use stigma intersect in this sample. Intersectional stigma has been

defined as the presence of a statistical interaction between two forms of stigma in several studies estimating the effect of intersectional stigma on health outcomes (15, 18, 19, 46). In our study, we adapted this concept of stigma co-existence to a situation where the intersectional stigma is an outcome, by defining intersectional stigma as the concurrent presence of high levels of both stigma scores. It is possible that categorizing the stigma variables misses certain aspects of stigma intersectionality: our previous qualitative research suggests that intersectional stigma manifests inconsistently, specific to varying contexts which the instruments we used did not capture. More work is needed to reach a consensus on instruments and statistical methods to quantify intersectional stigma (47).

Despite the lack of association between the potential predictors and intersectional stigma, our models were able to capture factors associated with HIV and substance use stigma. For example, this study confirms the association found in other studies between depressive symptoms and HIV stigma and substance use stigma (15, 48). Depressive symptoms are among the most common mental health symptoms experienced by PWH and they were present in 46% of the PWH with history of drug use included in this analysis (49, 50).

Our findings, suggesting that alcohol dependence in the past 12 month is associated with experiencing increased HIV and substance use stigma scores, are also consistent with previous studies in Russia and elsewhere (51). HIV and substance use stigma might reduce people's ability to address their alcohol use, possibly exacerbated by stigma-related stress and their maladaptive unhealthy alcohol use. Likewise, even in Russia, alcohol use that exceeds normative drinking might further increase people's vulnerability to HIV and substance use stigma and discrimination. Of note, over half of the study participants were at risk of alcohol dependence based on AUDIT screening, reflecting the inclusion criterion of heavy alcohol drinking for the nested randomized controlled trial in this cohort. This high prevalence is also representative of the widespread unhealthy alcohol consumption in Russia, particularly common among people with HIV and those with a history of other substance use (52–55).

In this study involving people with a lifetime history of drug use, more than a third of participants (38%) reported injection drug use in the past 30 days. We found that recent injection drug use correlated with both an increased substance use stigma score and with having any form of stigma score high versus low stigma, but not with HIV stigma or intersectional stigma. This is consistent with a previous study that found no link between substance use outcomes and HIV stigma in a similar population in St. Petersburg (56).

Some of our results are not supported by the literature on HIV and substance use stigma. For instance, several studies, mostly using qualitative methods, found that women experienced greater levels of substance use-related stigma than men (57–60) (29). In contrast, we detected no association between gender and either HIV or substance use stigma. The reason for this discrepancy is unclear and could be explained by the high level of stigmatization of people of both genders for their substance use and HIV (61). In a previous study in a similar population, we found that women were likely to experience sexual and other forms of violence, and future research should explore the stigma's role in this vulnerability (62).

Previous studies have found a protective relationship between social support and HIV-related stigma in PWH (63, 64). The lack of association between social support and HIV or substance use stigma in this study might be attributable to the generic measurement of social support, which did not assess the source of the potential support. In contrast, a prior study using a more specific social support instrument found that social support from friends, but not support from family or others, to be associated with less HIV stigma (65).

Although other studies have shown increased levels of HIV stigma among sex workers living with HIV (66, 67), we found no evidence of an association with report of transactional sex. This might be due to the small number (17 [8%]) of individuals who reported a history of selling sex and the consequent lack of statistical power to detect an association.

There are several limitations to this study that future work might expand upon. First, given this study's cross-sectional design, no conclusions can be drawn concerning causality or directionality, and thus additional research is needed to clarify the nature of the examined associations. Further qualitative research and future longitudinal studies with stigma data collection at multiple time points are needed to explore potential determinants of intersectional stigma and the mechanisms causing it. Second, although the Berger HIV stigma scale and the SASSS substance use stigma scale have been widely used, it is difficult to translate an observed magnitude of scores into a clinically meaningful effect. Third, we defined the outcome intersectionality based on the quartiles of the distribution of the HIV stigma score and of the substance use stigma score. We acknowledge that this limits the generalizability of our findings to populations with a different distribution of these two stigma scales. Fourth, many people in our study had a history of unhealthy alcohol use and, albeit this is not uncommon in this population, the findings from this study might thus not be representative of all people with HIV who use drugs in St. Petersburg or in Russia.

Conclusions

Among a cohort of PWH who reported a lifetime history of drug use in Russia, depressive symptoms and high risk of alcohol dependence were linked to higher levels of HIV stigma and of substance use stigma. Recent injection drug use was associated with higher levels of substance use stigma. We did not identify correlates of intersectional stigma in this population using our instruments.

Given the complex intersection of these two layered stigma identities, future studies should examine the longitudinal associations of HIV and substance use stigma among PWH with substance use to better understand factors and causal paths that lead to the co-existence of these forms of stigma in Russia and elsewhere. Such work is central to informing the urgently needed political, social, and clinical changes to promote access to HIV and addiction services in the key population of PWH who use drugs. Stigma interventions may be of value to help affected people cope with harmful substance use and with the negative effects of stigmatization.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Funding:

References

1. Goffman E Stigma: Notes on the Management of a Spoiled Identity Simon & Schuster, New York 1963.

2. Stangl AL, Earnshaw VA, Logie CH, van Brakel W,C Simbayi L, Barré I, et al. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. BMC Medicine 2019; 17(1):31. [PubMed: 30764826]

3. Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. AIDS Behav 2009; 13(6):1160–1177. [PubMed: 19636699]

4. Rankin WW, Brennan S, Schell E, Laviwa J, Rankin SH. The stigma of being HIV-positive in Africa. PLoS Med 2005; 2(8):e247. [PubMed: 16008508]

5. Baugher AR, Beer L, Fagan JL, Mattson CL, Freedman M, Skarbinski J, et al. Prevalence of Internalized HIV-Related Stigma Among HIV-Infected Adults in Care, United States, 2011–2013. AIDS Behav 2017; 21(9):2600–2608. [PubMed: 28213821]

6. Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav 2006; 10(5):473–482. [PubMed: 16604295]

7. Bogart LM, Wagner GJ, Green HD Jr., Mutchler MG, Klein DJ, McDavitt B. Social Network Characteristics Moderate the Association Between Stigmatizing Attributions About HIV and Non-adherence Among Black Americans Living with HIV: a Longitudinal Assessment. Ann Behav Med 2015; 49(6):865–872. [PubMed: 26296702]

8. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc 2013; 16(3 Suppl 2):18640. [PubMed: 24242258]

9. Overstreet NM, Earnshaw VA, Kalichman SC, Quinn DM. Internalized stigma and HIV status disclosure among HIV-positive black men who have sex with men. AIDS Care 2013; 25(4):466–471. [PubMed: 23006008]

10. Wolitski RJ, Pals SL, Kidder DP, Courtenay-Quirk C, Holtgrave DR. The effects of HIV stigma on health, disclosure of HIV status, and risk behavior of homeless and unstably housed persons living with HIV. AIDS Behav 2009; 13(6):1222–1232. [PubMed: 18770023]

11. Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med 2009; 24(10):1101–1108. [PubMed: 19653047]

12. Crapanzano KA, Hammarlund R, Ahmad B, Hunsinger N, Kullar R. The association between perceived stigma and substance use disorder treatment outcomes: a review. Subst Abuse Rehabil 2019; 10:1–12. [PubMed: 30643480]

13. Kulesza M, Larimer ME, Rao D. Substance Use Related Stigma: What we Know and the Way Forward. J Addict Behav Ther Rehabil 2013; 2(2).

14. Luoma JB, Kohlenberg BS, Hayes SC, Bunting K, Rye AK. Reducing self-stigma in substance abuse through acceptance and commitment therapy: Model, manual development, and pilot outcomes. Addict Res Theory 2008; 16(2):149–165. [PubMed: 27746709]

15. Earnshaw VA, Smith LR, Cunningham CO, Copenhaver MM. Intersectionality of internalized HIV stigma and internalized substance use stigma: Implications for depressive symptoms. J Health Psychol 2013.

16. Turan JM, Elafros MA, Logie CH, Banik S, Turan B, Crockett KB, et al. Challenges and opportunities in examining and addressing intersectional stigma and health. BMC Med 2019; 17(1):7. [PubMed: 30764816]

17. Jackson-Best F, Edwards N. Stigma and intersectionality: a systematic review of systematic reviews across HIV/AIDS, mental illness, and physical disability. BMC Public Health 2018; 18(1):919. [PubMed: 30049270]

18. Calabrese SK, Burke SE, Dovidio JF, Levina OS, Uuskula A, Niccolai LM, et al. Internalized HIV and Drug Stigmas: Interacting Forces Threatening Health Status and Health Service Utilization Among People with HIV Who Inject Drugs in St. Petersburg, Russia. AIDS Behav 2016; 20(1):85–97. [PubMed: 26050155]

19. Vetrova MV, Cheng DM, Bendiks S, Gnatienko N, Lloyd-Travaglini C, Jiang W, et al. HIV and Substance Use Stigma, Intersectional Stigma and Healthcare Among HIV-Positive PWID in Russia. AIDS Behav 2021.

20. Beyrer C, Wirtz AL, O'Hara G, Leon N, Kazatchkine M. The expanding epidemic of HIV-1 in the Russian Federation. PLoS Med 2017; 14(11):e1002462. [PubMed: 29182631]

21. Federal Scientific Center for the Prevention and Combat of AIDS of the Public Office of the Central Scientific Research Institute Rospotrebnadzor. Reference on HIV infection in the Russian Federation as of June 30, 2017 In; 2018.

22. Crime" UNOoDa. World Drug Report 2021 In:; 2021.

23. Sandelowski M, Lambe C, Barroso J. Stigma in HIV-positive women. J Nurs Scholarsh 2004; 36(2):122–128. [PubMed: 15227758]

24. Abel E Women with HIV and stigma. Fam Community Health 2007; 30(1 Suppl):S104–106. [PubMed: 17159623]

25. Women Visser M., HIV and Stigma. Future Virology 2012; 7(6):4.

26. Kulesza M, Raguram R, Rao D. Perceived mental health related stigma, gender, and depressive symptom severity in a psychiatric facility in South India. Asian J Psychiatr 2014; 9:73–77. [PubMed: 24813041]

27. Malave S, Ramakrishna J, Heylen E, Bharat S, Ekstrand ML. Differences in testing, stigma, and perceived consequences of stigmatization among heterosexual men and women living with HIV in Bengaluru, India. AIDS Care 2013; 26(3):396–403. [PubMed: 23869716]

28. Kane JC, Elafros MA, Murray SM, Mitchell EMH, Augustinavicius JL, Causevic S, et al. A scoping review of health-related stigma outcomes for high-burden diseases in low- and middle-income countries. BMC Med 2019; 17(1):17. [PubMed: 30764819]

29. Meyers SA, Earnshaw VA, D'Ambrosio B, Courchesne N, Werb D, Smith LR. The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature. Drug Alcohol Depend 2021; 223:108706. [PubMed: 33901753]

30. So-Armah KA, Cheng DM, Freiberg MS, Gnatienko N, Patts G, Ma Y, et al. Association between alcohol use and inflammatory biomarkers over time among younger adults with HIV-The Russia ARCH Observational Study. PLoS One 2019; 14(8):e0219710. [PubMed: 31437155]

31. Freiberg MS, Cheng DM, Gnatienko N, Blokhina E, Coleman SM, Doyle MF, et al. Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial. JAMA Netw Open 2020; 3(5):e204330. [PubMed: 32383748]

32. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993; 88(6):791–804. [PubMed: 8329970]

33. McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL, et al. New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis 1985; 173(7):412–423. [PubMed: 4009158]

34. Wechsberg W Revised risk behavior assessment, part I and part II NC; 1998.

35. Weatherby NN R; Cesari H; Booth R; McCoy CB.; Watters JK; Williams M; Chitwood DD;. Validity of self-reported drug use among injection drug users and crack smokers recruited through street outreach. Evaluation and Program Planning; 17(4):347–355.

36. Needle RF DG; Weatherby N; Chitwood D; Brown B; Cesari H; Booth R; Williams ML; Watters J; Andersen M; Braunstein M Reliability of self-reported HIV risk behaviors of drug users. Psychology of Addictive Behaviors 1995; 9(4):242–250.

37. Kazis LE, Miller DR, Clark JA, Skinner KM, Lee A, Ren XS, et al. Improving the response choices on the veterans SF-36 health survey role functioning scales: results from the Veterans Health Study. J Ambul Care Manage 2004; 27(3):263–280. [PubMed: 15287216]

38. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health 2001; 24(6):518–529. [PubMed: 11746080]

39. Luoma JB, Nobles RH, Drake CE, Hayes SC, O'Hair A, Fletcher L, et al. Self-Stigma in Substance Abuse: Development of a New Measure. J Psychopathol Behav Assess 2013; 35(2):223–234. [PubMed: 23772099]

40. Luoma JB, Twohig MP, Waltz T, Hayes SC, Roget N, Padilla M, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav 2007; 32(7):1331–1346. [PubMed: 17092656]

41. Cronbach LJ. Coefficient alpha and the internal structure of tests. psychometrika 1951; 16(3):297–334.

42. Fleishman JA, Sherbourne CD, Crystal S, Collins RL, Marshall GN, Kelly M, et al. Coping, conflictual social interactions, social support, and mood among HIV-infected persons. HCSUS Consortium. Am J Community Psychol 2000; 28(4):421–453. [PubMed: 10965385]

43. Chishinga N, Kinyanda E, Weiss HA, Patel V, Ayles H, Seedat S. Validation of brief screening tools for depressive and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Psychiatry 2011; 11:75. [PubMed: 21542929]

44. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Applied Psychological Measurement 1977; 1(3):385–401.

45. Rubinsky AD, Kivlahan DR, Volk RJ, Maynard C, Bradley KA. Estimating risk of alcohol dependence using alcohol screening scores. Drug Alcohol Depend 2010; 108(1–2):29–36. [PubMed: 20042299]

46. Sereda Y, Kiriazova T, Makarenko O, Carroll JJ, Rybak N, Chybisov A, et al. Stigma and quality of co-located care for HIV-positive people in addiction treatment in Ukraine: a cross-sectional study. J Int AIDS Soc 2020; 23(5):e25492. [PubMed: 32372534]

47. Kalichman SC, Shkembi B, Eaton LA. Finding the Right Angle: A Geometric Approach to Measuring Intersectional HIV Stigma. AIDS Behav 2021.

48. Earnshaw VA, Eaton LA, Collier ZK, Watson RJ, Maksut JL, Rucinski KB, et al. HIV Stigma, Depressive Symptoms, and Substance Use. AIDS Patient Care STDS 2020; 34(6):275–280. [PubMed: 32484742]

49. Klinkenberg WD, Sacks S, Hiv/Aids Treatment Adherence HO, Cost Study G. Mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care 2004; 16 Suppl 1:S22–42. [PubMed: 15736820]

50. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58(8):721–728. [PubMed: 11483137]

51. Lunze K, Lioznov D, Cheng DM, Nikitin RV, Coleman SM, Bridden C, et al. HIV Stigma and Unhealthy Alcohol Use Among People Living with HIV in Russia. AIDS Behav 2017; 21(9):2609–2617. [PubMed: 28600603]

52. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002; 63(2):179–186. [PubMed: 12033694]

53. Egbe CO, Dakum PS, Ekong E, Kohrt BA, Minto JG, Ticao CJ. Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. BMC Public Health 2017; 17(1):542. [PubMed: 28577548]

54. Dietze P, Jenkinson R, Aitken C, Stoove M, Jolley D, Hickman M, et al. The relationship between alcohol use and injecting drug use: impacts on health, crime and wellbeing. Drug Alcohol Depend 2013; 128(1–2):111–115. [PubMed: 22989499]

55. Degenhardt L, Hall W. Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug Alcohol Rev 2003; 22(1):7–13. [PubMed: 12745353]

56. Edelman EJ, Lunze K, Cheng DM, Lioznov DA, Quinn E, Gnatienko N, et al. HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. AIDS Behav 2017; 21(9):2618–2627. [PubMed: 28634662]

57. Sandelowski M, Barroso J, Voils CI. Gender, race/ethnicity, and social class in research reports on stigma in HIV-positive women. Health Care Women Int 2009; 30(4):273–288. [PubMed: 19255883]

58. Carr RL, Gramling LF. Stigma: a health barrier for women with HIV/AIDS. J Assoc Nurses AIDS Care 2004; 15(5):30–39.

59. Ho SS, Holloway A. The impact of HIV-related stigma on the lives of HIV-positive women: an integrated literature review. J Clin Nurs 2015.

60. Spooner C, Saktiawati AM, Lazuardi E, Worth H, Subronto YW, Padmawati RS. Impacts of stigma on HIV risk for women who inject drugs in Java: A qualitative study. Int J Drug Policy 2015.

61. Kulesza M, Matsuda M, Ramirez JJ, Werntz AJ, Teachman BA, Lindgren KP. Towards greater understanding of addiction stigma: Intersectionality with race/ethnicity and gender. Drug Alcohol Depend 2016; 169:85–91. [PubMed: 27792911]

62. Lunze K, Raj A, Cheng DM, Quinn EK, Lunze FI, Liebschutz JM, et al. Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia - a mixed methods study. J Int AIDS Soc 2016; 19(4 Suppl 3):20877. [PubMed: 27435712]

63. Takada S, Weiser SD, Kumbakumba E, Muzoora C, Martin JN, Hunt PW, et al. The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med 2014; 48(1):26–37. [PubMed: 24500077]

64. Colbert AM, Kim KH, Sereika SM, Erlen JA. An examination of the relationships among gender, health status, social support, and HIV-related stigma. J Assoc Nurses AIDS Care 2010; 21(4):302–313. [PubMed: 20116295]

65. Galvan FH, Davis EM, Banks D, Bing EG. HIV stigma and social support among African Americans. AIDS Patient Care STDS 2008; 22(5):423–436. [PubMed: 18373417]

66. Benoit C, McCarthy B, Jansson M. Stigma, sex work, and substance use: a comparative analysis. Sociol Health Illn 2015; 37(3):437–451. [PubMed: 25688450]

67. King EJ, Maman S, Bowling JM, Moracco KE, Dudina V. The influence of stigma and discrimination on female sex workers' access to HIV services in St. Petersburg, Russia. AIDS Behav 2013; 17(8):2597–2603. [PubMed: 23525789]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table I.

Demographic and clinical characteristics of 208 persons with HIV and a lifetime history of drug use.

Age	Median [IQR]		34 [31, 37]
Gender	N (%)	Male	141 (67.8)
		Female	67 (32.2)
Time since HIV Diagnosis	N (%)	1 year	192 (92.3)
		< 1 year	16 (7.7)
Education	N (%)	> 9 grades	162 (77.9)
		9 grades	46 (22.1)
Employment	N (%)	Working full or part time	101 (48.6)
		Not employed	107 (51.4)
CES-D Depression Scale	N (%)	Moderate to severe depressive symptoms (16)	95 (45.7)
		<16	113 (54.3)
Alcohol dependence (AUDIT)	N (%)	Yes	116 (55.8)
		No	92 (44.2)
Recent Drug Use (past 30 days)	N (%)	Yes	90 (43.3)
		No	118 (56.7)
Recent injection drug use (past 30 Day)	N (%)	Yes	81 (38.9)
		No	127 (61.1)
Ever sold sex for money, alcohol, drugs	N (%)	Yes	17 (8.3)
		No	189 (91.7)
		Missing	2
CD4 Count	N (%)	500	70 (43.8)
		< 500	90 (56.3)
		Missing	48
Social Support Scale	N (%)	75th percentile	79 (38.0)
		< 75th percentile	129 (62.0)

Table II.

Unadjusted and adjusted linear regression models for correlates of HIV stigma score and substance use stigma score among PWH with a lifetime history of drug use.

	Outcome			
	HIV stigma		Substance use stigma [a]	
Predictors	Unadjusted β (95% CI)	Adjusted β (95% CI)	Unadjusted β (95% CI)	Adjusted β (95% CI)
Social support (High vs. Low)	−1.45 (−3.03, 0.12)	−0.26 (−1.75, 1.23)	−0.15 (−2.94, 2.64)	2.48 (−0.01, 4.97)
Recent injection drug use (past 30 Day)	1.01 (−0.56, 2.59)	−0.09 (−1.58, 1.40)	6.35 (3.72, 8.99) **	4.71 (2.22, 7.21) **
Moderate to severe depressive symptoms (CES-D score 16 vs < 16)	4.50 (3.08, 5.92) **	4.01 (2.55, 5.47) **	8.05 (5.57, 10.53) **	6.99 (4.54, 9.43) **
Gender (Female vs. Male)	1.18 (−0.46, 2.83)	1.12 (−0.42, 2.66)	−0.95 (−3.85, 1.94)	−1.29 (−3.87, 1.30)
Alcohol Dependence (AUDIT) (yes versus no)	2.30 (0.78, 3.82) **	1.68 (0.22, 3.15) *	4.94 (2.30, 7.58) **	3.31 (0.85, 5.76) **
Transactional sex (yes vs no)	3.31 (0.55, 6.08) *	2.25 (−0.36, 4.87)	3.72 (−1.18, 8.62)	3.10 (−1.29, 7.49)
Time since HIV diagnosis (1 vs. <1 year)	0.04 (−2.85, 2.94)	−1.02 (−3.74, 1.69)	−0.93 (−6.01, 4.15)	−4.24 (−8.78, 0.31)

Note:

*
indicates a p-value <0.5

**
indicates a p-value <0.01

Table III.

Unadjusted and adjusted odds ratios from a multinomial logistic regression model assessing the association between potential predictors and intersectional HIV and substance use stigma among PWH with a lifetime history of drug use.

	Outcome			
	Intersectional stigma versus single stigma		**Single stigma versus low stigma**	
Predictors	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Social support				
Low	1	1	1	1
High	0.78 (0.38,1.60)	1.01 (0.47,2.17)	0.96 (0.50,1.83)	1.77 (0.81,3.86)
Recent injection drug use (past 30 Day)				
No	1	1	1	1
Yes	1.34 (0.67,2.68)	1.20 (0.58,2.49)	1.80 (0.92,3.55)	1.40 (0.65,3.02)
Moderate to severe depressive symptoms				
No (CES-D < 16)	1	1	1	1
Yes (CES-D ≥ 16)	2.25 (1.07,4.76) *	2.10 (0.96,4.58)	6.71 (3.13,14.50) **	8.06 (3.52,18.52) **
Gender				
Male	1	1	1	1
Female	0.80 (0.39,1.67)	0.81 (0.37,1.76)	1.44 (0.72,2.85)	1.45 (0.65,3.24)
Alcohol dependence (AUDIT)				
No	1	1	1	1
Yes	1.75 (0.83,3.67)	1.58 (0.73,3.39)	2.18 (1.14,4.17) **	2.54 (1.18,5.49) *
Time since HIV diagnosis				
<1 year	1	1	1	1
1 year	1.26 (0.39,4.08)	0.93 (0.27,3.23)	0.33 (0.09,1.31)	0.10 (0.02,0.57) **
Transactional sex				
No	1	1	1	1
Yes	1.37 (0.45,4.15)	1.41 (0.43,4.58)	2.54 (0.63,10.20)	0.71 (0.22,2.32)

Note:

*
indicates a p-value <0.5

Author Manuscript

**indicates a p-value <0.01

Author Manuscript

Author Manuscript

Author Manuscript